Receptor tyrosine kinase inhibitors

P. Haluska, Alex Adjei

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Receptor tyrosine kinases (RTKs) are a diverse group of transmembrane proteins involved in signal transduction. Their function in many cell types is to drive a wide variety of cellular functions, including growth, differentiation and angiogenesis, by transducing growth factor signals from the external milieu to intracellular processes. In malignancies, these pathways are often exploited by tumor cells to optimize tumor growth and metastasis. Indeed, alterations in RTK pathways have been implicated in oncogenic activation, tumor angiogenesis and mitogenic stimulation. Thus, RTKs are logical targets for novel anticancer agent development. There are currently a large number of small-molecule RTK antagonists in phase I to III clinical development. These agents inhibit the intracellular tyrosine kinase activity of receptors for epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF). The biology and results of clinical trials with these agents will be discussed.

Original languageEnglish (US)
Pages (from-to)280-286
Number of pages7
JournalCurrent Opinion in Investigational Drugs
Volume2
Issue number2
StatePublished - 2001

Fingerprint

Receptor Protein-Tyrosine Kinases
Neoplasms
Fibroblast Growth Factors
Platelet-Derived Growth Factor
Growth
Epidermal Growth Factor
Antineoplastic Agents
Vascular Endothelial Growth Factor A
Signal Transduction
Intercellular Signaling Peptides and Proteins
Clinical Trials
Neoplasm Metastasis
Proteins

Keywords

  • EGF
  • FGF
  • Growth factors
  • PDGF
  • Signal transduction
  • VEGF

ASJC Scopus subject areas

  • Pharmacology

Cite this

Receptor tyrosine kinase inhibitors. / Haluska, P.; Adjei, Alex.

In: Current Opinion in Investigational Drugs, Vol. 2, No. 2, 2001, p. 280-286.

Research output: Contribution to journalArticle

@article{80d9eb459e854e7aac78b31d493a14c9,
title = "Receptor tyrosine kinase inhibitors",
abstract = "Receptor tyrosine kinases (RTKs) are a diverse group of transmembrane proteins involved in signal transduction. Their function in many cell types is to drive a wide variety of cellular functions, including growth, differentiation and angiogenesis, by transducing growth factor signals from the external milieu to intracellular processes. In malignancies, these pathways are often exploited by tumor cells to optimize tumor growth and metastasis. Indeed, alterations in RTK pathways have been implicated in oncogenic activation, tumor angiogenesis and mitogenic stimulation. Thus, RTKs are logical targets for novel anticancer agent development. There are currently a large number of small-molecule RTK antagonists in phase I to III clinical development. These agents inhibit the intracellular tyrosine kinase activity of receptors for epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF). The biology and results of clinical trials with these agents will be discussed.",
keywords = "EGF, FGF, Growth factors, PDGF, Signal transduction, VEGF",
author = "P. Haluska and Alex Adjei",
year = "2001",
language = "English (US)",
volume = "2",
pages = "280--286",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Receptor tyrosine kinase inhibitors

AU - Haluska, P.

AU - Adjei, Alex

PY - 2001

Y1 - 2001

N2 - Receptor tyrosine kinases (RTKs) are a diverse group of transmembrane proteins involved in signal transduction. Their function in many cell types is to drive a wide variety of cellular functions, including growth, differentiation and angiogenesis, by transducing growth factor signals from the external milieu to intracellular processes. In malignancies, these pathways are often exploited by tumor cells to optimize tumor growth and metastasis. Indeed, alterations in RTK pathways have been implicated in oncogenic activation, tumor angiogenesis and mitogenic stimulation. Thus, RTKs are logical targets for novel anticancer agent development. There are currently a large number of small-molecule RTK antagonists in phase I to III clinical development. These agents inhibit the intracellular tyrosine kinase activity of receptors for epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF). The biology and results of clinical trials with these agents will be discussed.

AB - Receptor tyrosine kinases (RTKs) are a diverse group of transmembrane proteins involved in signal transduction. Their function in many cell types is to drive a wide variety of cellular functions, including growth, differentiation and angiogenesis, by transducing growth factor signals from the external milieu to intracellular processes. In malignancies, these pathways are often exploited by tumor cells to optimize tumor growth and metastasis. Indeed, alterations in RTK pathways have been implicated in oncogenic activation, tumor angiogenesis and mitogenic stimulation. Thus, RTKs are logical targets for novel anticancer agent development. There are currently a large number of small-molecule RTK antagonists in phase I to III clinical development. These agents inhibit the intracellular tyrosine kinase activity of receptors for epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF). The biology and results of clinical trials with these agents will be discussed.

KW - EGF

KW - FGF

KW - Growth factors

KW - PDGF

KW - Signal transduction

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=0035116613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035116613&partnerID=8YFLogxK

M3 - Article

C2 - 11816845

AN - SCOPUS:0035116613

VL - 2

SP - 280

EP - 286

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 2

ER -